Low-Dose Naltrexone for Pruritus in Systemic Sclerosis PDF Print E-mail
Thursday, 01 March 2012 16:43
Tracy Frech, Kirsten Novak, Monica P. Revelo, Maureen Murtaugh, Boaz Markewitz, Nathan Hatton, Mary Beth Scholand, Edward Frech, David Markewitz, and Allen D. Sawitzke
Received 31 May 2011; Accepted 14 July 2011


Systemic sclerosis (SSc; scleroderma) is an autoimmune disease characterized by vasculopathy and fibrosis of multiple organs including the skin, lungs, and gastrointestinal tract (GIT). This chronic disease process results in pain and pruritus, two distinct, but interacting phenomena. Pruritus is most common in the early stages of disease and may subside as the disease progresses. SSc patients that complain of pruritus have more significant skin involvement, more severe finger ulcers, worse respiratory symptoms, and a greater number of GIT complaints. Of interest, pruritus is independently associated with GIT symptoms in SSc. Although pruritus is associated with significant disability, management guidelines for pruritus in SSc do not exist.

Pruritus is also a feature of primary biliary cirrhosis (PBC), which occurs more commonly in SSc than the normal population. There is a known association with PBC and oxidative stress as well as endothelial dysfunction. Pharmaceutical management suggestions for treatment of pruritus in PBC include cholestyramine, rifampin, sertraline, and naloxone. More recently, pilot trials of low-dose naltrexone hydrochloride (LDN), which is a pharmaceutical similar to naloxone, have recently gained increasing recognition for treating chronic pain associated with fibromyalgia, multiple sclerosis, and Crohn’s disease.

Evidence supporting the hypotheses that increased opioid-mediated neurotransmission in the brain is a mechanism of pruritus and that central opioidergic tone is increased in cholestasis provides a rationale for treating the pruritus of cholestasis with opiate antagonists in PBC. Another potential mechanism of action of LDN is through attenuation of the production of proinflammatory cytokines and superoxides potentially mediated by activity of toll-like receptor. Modulation of mitochondrial apoptosis has also been proposed as a mechanism of LDN. In SSc, oxidative stress may be important in disease pathogenesis. Thus, an agent that potentially modulates oxidative stress is attractive as an emerging therapeutic in SSc. Given the putative mechanisms of action of LDN and the roles of these various pathways in SSc, our hypothesis is that LDN may be a reasonable agent to treat pruritus in SSc.

Continue reading the full review article, by downloading it from the link provided below.

 
More articles :

» Our Donors

The Scleroderma Care Foundation wishes to express our appreciation and gratitude for the generosity and support extended to us, by all of our donors to date, and the list keeps on growing. Your contributions have all been incredibly helpful and...

» Pulmonary Arterial Hypertension And Scleroderma

is a disease that affects the skin and internal organs. The literal meaning of the word is "hard skin"; people with Scleroderma experience a hardening and tightening of their skin. The inflammation and scarring associated with Scleroderma can cause...

» Preterm Delivery a Risk in Systemic Sclerosis

Many women with systemic sclerosis can have successful pregnancies, but the rates of preterm birth, low birth weight, and intrauterine growth restriction are approximately twice as high in these women compared to the general population of pregnant...

» Erectile Dysfunction is Frequent in Systemic Sclerosis and Associated with Severe Disease: A Study of the EULAR Scleroderma Trial and Research Group

Chingching Foocharoen, Alan Tyndall, Eric Hachulla, Edoardo Rosato, Yannick Allanore, Dominique Farge-Bancel, Paola Caramaschi, Paolo Airó, Starovojtova M Nikolaevna, José A Pereira da Silva, Bojana Stamenkovic, Gabriela Riemekasten, Simona...

» Autoimmune Diseases May Increase Cancer Risk

A new study reveals that patients with certain autoimmune diseases are more likely to develop cancer. The new information could help doctors diagnose cancer at a much earlier stage.Two years ago, 67- year- old Dorothy Adams noticed a thickening and...

» Development of an Activity Index for Localized Scleroderma (Morphea)

E. Lanciano, A. CHIALà, E. Praino, V. Grattagliano, M. Covelli, F. Iannone, G. Lapadula Reumatologia Universitaria, Policlinico, Bari, ItalyAnn Rheum Dis 2011;70(Suppl3):481Background: Morphea is a skin disorder characterized by fibrosis. It...